Five-week raloxifene hydrochloride response in ovariectomized rats
Animal study · Female Sprague–Dawley rats, 10–11 weeks old at acquisition; dosing started after ovariectomy recovery; repeated five-week dose-response design. [1]
Raloxifene partly preserved femoral BMD and lowered serum cholesterol. Uterine wet weight increased modestly without significant changes in measured histology scores; tissue selectivity does not imply no uterine response.
| Endpoint | Reported result | Reference |
|---|---|---|
| Distal femoral metaphysis BMD relative to intact controls | BMD relative to intact 88–90% at 0.1–10 mg/kg/day | [1] |
| Serum cholesterol decrease relative to OVX controls | Reported percentage decrease 37% at 0.1 mg/kg/day; 67% at 10 mg/kg/day | [1] |
| Uterine wet weight after five weeks | Mean ± SEM OVX: 127 ± 5 mg; raloxifene 0.1 mg/kg/day: 196 ± 5 mg; raloxifene 10 mg/kg/day: 186 ± 4 mg | [1] |
| Uterine epithelial height, myometrial thickness, stromal expansion, eosinophilia and composite estrogenicity scores | Statistical comparison No statistically significant raloxifene effect versus OVX controls on reported histology scores | [1] |
| Serum triglycerides | Statistical comparison No significant change with raloxifene or ethynyl estradiol versus OVX controls | [1] |
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Daily
- Treatment course
- 5 weeks
- Vehicle
- 1.5% carboxymethylcellulose
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Raloxifene hydrochloride dose-response groups 0.01–10 mg/kg/day; endpoint-specific dose sets in Figures 2/4 and Table II. | OVX vehicle; intact controls; 17α-ethynyl estradiol 0.1 mg/kg/day comparator. | Partial BMD protection and cholesterol reduction; modest uterine wet-weight increase without significant changes in reported histology scores. Triglycerides unchanged. | [1] |
- Raloxifene hydrochloride dose-response groups
- Model: Female ovariectomized Sprague–Dawley rats
- Reported limits: Endpoint-specific sample sizes differ; animal-level overlap is not established.
Methods and source locations
Compound reported in the paper: Raloxifene hydrochloride; Compound label in the paper: LY139481 HCl
Preclinical evidence for the reported Lilly HCl material; no Adooq sourcing/lot validation.
Methods p.64; Results pp.64–66; Figures 2 and 4 with captions p.65; Tables I–II and footnotes p.66
Distal femoral metaphysis BMD relative to intact controls: Single-photon absorptiometry; Figure 2 mean ± SEM combines six experiments: intact n=28, OVX n=29, raloxifene n=30 per dose, estrogen n=12. Significantly above OVX but below intact controls, P < 0.05. — Results: Bone p.64; Figure 2/caption p.65; Methods p.64
Serum cholesterol decrease relative to OVX controls: Colorimetric assay; Figure 4 mean ± SEM: intact and OVX n=6 each, raloxifene n=12 per group, estrogen n=6; P < 0.05 versus OVX. — Results: Serum lipids and Figure 4/caption p.65; Serum assays p.64
Uterine wet weight after five weeks: Table II; n=6–12 per group, exact group-specific n not given. These raloxifene groups differ from OVX at P < 0.05 by Scheffé range test. — Table II/footnotes p.66; Results: Uterus p.65; Methods p.64
Uterine epithelial height, myometrial thickness, stromal expansion, eosinophilia and composite estrogenicity scores: Blinded semiquantitative histology. Table II reports relative scores, not absolute cell-height units; mean ± SEM for n=6–12 per group. Ethynyl estradiol increased these scores. — Uterine histology/Statistics p.64; Results pp.65–66; Table II p.66
Serum triglycerides: Enzymatic serum assay; Table I reports mean ± SEM for 6–12 rats per group. — Serum assays p.64; Serum lipids p.65; Table I p.66
Raloxifene hydrochloride dose-response groups · Methods p.64; Results pp.64–66; Figures 2 and 4 with captions p.65; Tables I–II and footnotes p.66